FHTX: Foghorn Price-to-Sales Ratio

Symbol and logo of brand Foghorn Therapeutics (FHTX)

Foghorn Therapeutics' price-to-sales ratio is sensitive to global logistics risks and patent disputes in Asia, with 1.10 determining the current level of this parameter. A lack of pricing power due to its pre-commercial status leaves Foghorn Therapeutics dependent on major partners. The efficiency of research into blood cancer genetics is maintained by outsourcing production and testing to external contractors.

FHTX Foghorn Therapeutics Inc. P/S Multiple (07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for Foghorn Therapeutics (FHTX)

- stock price and consensus target price:
Share Price foghorntx.com|FHTX - Analyst Consensus Forecast
- market capitalization information:
Market Valuation Foghorn|FHTX - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Foghorn Therapeutics|FHTX - Book Capitalization|Market Value to Equity Ratio foghorntx.com|FHTX - Company Total Assets
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Foghorn Therapeutics|FHTX - Long-Term Debt to Equity|Current Liabilities to Capital foghorntx.com|FHTX - Company Debts|Debt to Net Assets Ratio Foghorn|FHTX - Company Long-Term Debt|Company Short-Term Indebtedness Foghorn Therapeutics|Intermediate Coverage Ratio foghorntx.com
- earnings and multiples data:
FHTX - Net Income|Future Net Profit Foghorn Therapeutics|FHTX - P/E Multiple|Future Price to Earnings Multiple foghorntx.com|FHTX - PEG Multiple|Company Value to EBITDA Foghorn|FHTX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Foghorn Therapeutics|FHTX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth foghorntx.com|FHTX - Earnings per share growth in current year|Net earnings per share change forecast for next year Foghorn Therapeutics
- issuer revenue and sales details:
FHTX - Revenue and Sales Volume|Company Expected Sales Volume foghorntx.com|FHTX - Market Cap to Revenue|Forward P/S Multiple Foghorn
Fundamental company analysis:Foghorn Therapeutics, Inc., FHTX
Finished products of Foghorn

Foghorn Therapeutics (FHTX) is attracting leading chromatin specialists to develop innovative oncology therapies. The market cap-to-revenue ratio digitizes the value of these intellectual assets, enabling the identification of sustainable price corridors and a real valuation floor through the P/S multiple trend, while eliminating capital freeze risks associated with ignoring currency revaluations and export factors.

Competitors of Foghorn Therapeutics

tgtherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple ACLX (Arcellx, Inc.)|IRON (Disc Medicine Inc) - Price-to-Sales Ratio|SNDX - Price-to-Revenue Ratio|Price to Sales Kura|ADCT: P/S Multiple|Price-to-Revenue Multiple vorbio.com VOR|NKTX (Nkarta Inc.) - P/S Multiple|COEP: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Actinium Pharmaceuticals Inc (ATNM)|ESLA - Price to Sales|Price-to-Revenue Ratio CASI Pharmaceuticals, Inc. CASI|Market Capitalization-to-Revenue Ratio MRKR|INAB - Price-to-Revenue Ratio|ERNA (Eterna Therapeutics) - Market Cap to Revenue Ratio|GTBP (GT Biopharma Corp) - Market Cap to Revenue|Aptose Biosciences - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BPTH|MEIP (meipharma.com) - Market Cap to Sales Volume|P/S Multiple VINC